INTRODUCTION
Most autoimmune disorders are genetically complex and clinically heterogeneous. Classification permits physicians to distinguish individual autoimmune criteria based on the typical clinical features. However, underlying these separate clinical features, there is a genetic continuum of susceptibility factors and molecular pathways leading to autoimmunity. This becomes clear when analyzing existing genetic data according to clinical subphenotypes, reducing the overall genetic heterogeneity in the analyses (1 -8) . This has been clearly demonstrated in rheumatoid arthritis (RA), in which separating anti-citrullinated protein antibody positive and negative cases resulted in a far more homogeneous genetic analysis revealing genetic subgroups (1,3 -6) . The aim of personalized medicine is thus to accomplish a degree of resolution that allows us to distinguish genetically and molecularly such groups and provide more targeted therapeutic interventions.
There is a growing body of evidence that all autoimmune disorders share to a varying degree their genetic susceptibility loci (9) . It is clear that lack of statistical power due to limited sample size is a barrier to completely defining the genetic contribution to autoimmunity. As we increase our sample size, we can identify additional genes shared by some diseases but not shared by others. From the viewpoint that all autoimmune disorders are heterogeneous entities whose specific manifestations depend on the presence of several susceptibility genetic variants and
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Human Molecular Genetics, 2013, Vol. 22, No. 19 environmental triggers, the combined analysis of different autoimmune disorders will greatly increase our statistical power to detect modest genetic effects shared among them. This approach has already been successfully used to detect the shared genetic susceptibility component of RA, celiac disease, psoriasis and Crohn's disease (10) (11) (12) . In the present study, we meta-analyze the GWASs of two autoimmune disorders that have been demonstrated to share a relatively large portion of their genetic component and clinical features: systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) (13, 14) , identifying new loci for each disease. We would suggest a similar approach for other autoimmune diseases in the future.
RESULTS
The overall process followed during this study is illustrated in Figure 1 and described in detail in the Materials and methods section. Briefly, from the pan-meta-analysis of the SSc and SLE GWAS (15,16), we selected all SNPs which presented a GC-corrected P-value of ,5 × 10
26
. From these, we further selected for replication all SNPs which were associated with both diseases independently at nominal level. For a more detailed description of the selection criteria, see the Materials and methods section.
According to these selection criteria, we investigated 19 SNPs whose statistics are shown in Table 1 and Figure 2 . According to the significance criteria established (see Materials and methods section), we could confirm one new association shared by SSc (more specifically in the limited cutaneous subtype) and SLE: rs2275247 in KIAA0319L (combined P-value ¼ 1.40 × 10
210
, OR ¼ 1.51; SSc P-value ¼ 3.92 × 10
26
; SLE P-value ¼ 4.44 × 10
) (Table 1 ). Furthermore, we were able to determine two new genetic susceptibility regions at genome-wide level of significance in the combined analysis of SSc which had been previously described only in SLE: PXK (rs2176082, combined P-value ¼ 5.24 × 10
211
, OR ¼ 1.21; SSc P-value ¼ 4.44 × 10
27
; SLE P-value ¼ 1.12 × 10
25
) and JAZF1 (combined P-value ¼ 1.60 × 10
28
, OR ¼ 1.14; SSc P-value ¼ 3.63 × 10
25
; SLE P-value ¼ 1.19 × 10
24
) but with a modest association particularly for the SSc analysis alone. This suggests a minor role of these genetic variants in SSc compared with SLE (Table 1) . It is noteworthy that the associations present in the KIAA0319L and PXK regions were still significant at GWAS level after including as covariates the first three principal components in a logistic regression model, while the association in the JAZF1 was slightly reduced below GWAS level after this (the P-value not corrected for principal components was 1.60 × 10 28 and after principal component correction was 5.52 × 10
28
), which suggests minor population stratification for this SNP (Table 1) .
In whole blood gene expression data, we observed that KIAA0319L was significantly overexpressed in SLE patients compared with unaffected controls [P ¼ 5.36 × 10
25
, false discovery rate (FDR) ¼ 2.94 × 10
23
] with a fold change of 1.9, while in SSc, there was a trend towards overexpression compared with healthy individuals (P ¼ 9.05 × 10
, FDR ¼ 0.14) with a fold change of 1.3 . No significant expression differences were observed for PXK and JAZF1 in either SSc or SLE compared with controls (Table 2) .
Finally, we wanted to address how the biological processes are differentially distributed and shared between SSc and SLE. For this, we assigned each SNP with a P-value of ,0.05 and 5 × 10 26 to a gene (allowing a 20 kb window surrounding it). With this we were able to determine whether any particular biological process was overrepresented among these two sets of GWAS association (P , 0.05 and P , 5 × 10 26 ). As observed in Table 3 , the biological processes most significantly overrepresented among the SSc and SLE associated genes were those belonging to the immune system (27 processes for SSc, being the best P-value ¼ 2.05 × 10
213
; and 8 processes for SLE being the best P ¼ 2.14 × 10
28
). Among these immune system processes involved in SSc and SLE, the topmost one was cellular response to interferon-gamma (GO term 0071346). Another set of processes apparently shared by SSc and SLE were those related to the nervous system, while signaling, molting and cell adhesion were exclusively overrepresented among the SSc associated genes (Table 3) .
DISCUSSION
Utilizing a GWAS pan-meta-analysis strategy, we were able to identify a total of three new autoimmunity susceptibility loci, all of which are new for SSc and one of which is new for SLE. These new genetic susceptibility loci were undetected in the previous SSc and SLE GWASs due to the lack of statistical power.
The clearest example of this is rs2275247 in KIAA0319L, with a minor allele frequency of 3.43% in our GWAS cohorts, which would have gone undetected as Supplementary Material, Table S1 , predicts. However, due to the combined analysis, we were able to capture this association in our meta-analysis. KIAA0319L was previously associated with learning and cognition disabilities (17) . Interestingly, the protein contains among its evolutionary conserved domains a polycystic kidney disease domain, which is an immunoglobulin family-like domain of unclear function (18) . Furthermore, KIAA0319L was significantly overexpressed in peripheral blood cells from SLE patients compared with those of healthy controls, also showed that a similar trend was observed in SSc (Table 2) . Another possible lead pointing to the role of KIAA0319L in autoimmunity can be found in Fig. S2 ). Meanwhile, PXK and JAZF1 were previously described as SLE genetic risk factors (15, 19) . The role of these three genes in SLE pathogenesis remains largely unknown, it is also unclear whether their pathogenic mechanism is the same or different in SSc. However, PXK has been described to be involved in the trafficking of the epidermal growth factor receptor, which poses an attractive role in both SSc and SLE (20) . Furthermore, PXK has been described to be associated only with autoantibody production in SLE in a small cohort (21) , analogously to what we have observed in SSc in this study ( Table 1) . As of JAZF1, it has been associated with skeletal frame size and height, relating it to bone morphogenesis and collagen deposit (22, 23) , a key process in disorders affecting skin such as SSc and SLE.
In GWAS data, we could classify the genetic associations into three groups: Tier 1 for the GWAS-level associations (P , 5 × 10 28 ), Tier 2 for suggestive associations (P , 5 × 10
26
) and Tier 3 (all the remaining associations until 0.05). In the analysis of biological processes performed in this study (Table 3, Supplementary Material, Table S2 ), we used two sets of genes: first the Tier 1 and Tier 2 associations (stronger associations in general with better P-values and ORs) and the Tier 3 associations, in which, should there be any true genetic association, it would be weaker. When using all SNPs (translated to nearby genes) from Tiers 1 and 2 in this analysis, we observed that many biological processes gathered under the immune system label are important for both SSc and SLE, which is to be expected. Still in the Tier 1 and 2 associations, we see that signaling processes (cytokine mediated) and molting (to process by which the external layers of complex living beings is renewed) are also important to SSc. In fact, we have already seen this in SSc genetic studies which have described genes involved in morphogenesis and fibrosis to play a role in this disease (2, 16, 24) . Conversely, when we perform the biological process analysis including the Tier 3 genes, we observe that genes involved in the nervous system are important to both SSc and SLE (although different specific biological processes, Supplementary Material, Table S2 ) and cell adhesion is important to SSc. These biological processes being involved in SSc and SLE make sense based on the current knowledge (25) (26) (27) (28) (29) (30) (31) (32) (33) , but so far we have failed to find the specific genetic markers which could induce the neurological complications of SLE or SSc or cell adhesion in SSc.
Often, the association of a genetic variant with a trait is referred to by some gene in the same region, picked by its proximity or functional attractiveness considering the studied trait. Nevertheless, we also wanted to asses whether any of the described associations with SSc or SLE were in the same region and represented the same signal attributed by different genes. For this, we performed a GRAIL analysis (34) , taking into account all described genetic associations with a P-value of ,5 × 10 24 in the bibliography with any of the diseases. As seen in Figure 3 , all of the associated regions are represented by the previously described genes in those regions, with one notable exception: in the genetic region represented by the association of rs12540874, the association was attributed to GRB10 in SSc (2) and to IKZF1 in SLE (15) . Indeed, the signals were different in the studies by Gorlova et al. and Harley et al., but according to the GRAIL analysis the most plausible associated gene based on the current knowledge is IKZF1 (having connections with 12 other genes in the analysis) rather than GRB10 (0 connections according to the literature on the other genes).
Due to the increased statistical power derived from the merging of two GWASs in SSc and SLE and the addition of large replication cohorts, we were able to establish one new functionally attractive susceptibility locus for SSc and SLE (KIAA0319L) and two new susceptibility loci for SSc (PXK and JAZF1) at GWAS level. This study, together with several others, adds evidence for the genetic continuum that underlies SSc, SLE and most autoimmune disorders.
MATERIALS AND METHODS

Study cohorts
The GWAS cohorts analyzed in this study were composed of a total of 3530 cases and 7381 healthy controls. Of these, 2761 cases and 3720 healthy controls belonged to a previous SSc GWAS conducted on cohorts from Spain, Germany, The Netherlands and USA (16) . The rest of the cases and controls belonged to a previously published SLE GWAS conducted in the USA, SLEGEN cohort composed of 769 SLE patients and 3661 healthy controls (15) (Supplementary Material, Tables S3  and S4) .
We selected independent SSc and SLE replication cohorts in order to confirm the results observed in the previous meta-GWAS stage. The SSc replication cohort was composed of 432 cases and 380 controls from Spain, 691 cases and 241 controls from Italy and 455 cases and 2826 controls from the UK, while the SLE replication cohort was composed of 375 cases and 380 controls from Spain, 335 cases and 240 controls from Italy and 1017 cases and 2826 controls from the UK (Supplementary Material, Table S3 ). Supplementary Material, Table S4 , shows key features of the SSc cohorts analyzed. All the samples in the replication cohorts were recruited from hospitals and clinics of each country after approval by the corresponding ethics committees. Genotype data from the UK replication controls were obtained from the WTCCC data repositories, for which we were granted access.
All cases either met the American College of Rheumatology preliminary criteria for the classification of SSc (35) or had at least three of the five CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) features and were classified according to their skin involvement and their auto-antibody production status (36, 37) . All SLE patients in the current study fulfilled the revised criteria for classification of SLE from the American College of Rheumatology (38) . All individuals enrolled in the present study provided written informed consents.
Data quality control
GWAS data were filtered as previously described (16) using as a limits a 90% success call rate per SNP and individual, a deviation from the Hardy -Weinberg equilibrium of a P-value ,0.0001 and a minor allele frequency ,1%. The first 10 principal components were estimated and individuals who deviated more than three standard deviations from the centroid of their population in the first two principal components were excluded as outliers. The replication cohorts were filtered in the same way. The data for PCA adjustment in the logistic regression were obtained from Immunochip and GWAS data of our replication cohorts, except for the 455 SSc UK cases.
Genotyping
The GWAS genotyping of the SSc cases and controls was performed as follows: the Spanish SSc cases and controls together with Dutch and German SSc cases were genotyped at the Department of Medical Genetics of the University Medical Center Utrecht (The Netherlands) using the commercial release Illumina Human CNV370K BeadChip. Genotype data for Dutch and German controls were obtained from the Illumina Human 550KBeadChip available from a previous study. The SSc case group from the USA was genotyped at the Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, North Shore Long Island Jewish Health System using the Illumina Human 610-Quad BeadChip. CGEMS and Illumina iControl DBcontrols were genotyped on the Illumina Hap550KBeadChip. SNPs selected for the replication phase were genotyped in the Significantly overexpressed genes are marked in bold.
a PXK was not sufficiently expressed in whole blood samples and did not pass the filtering criteria. 
Study design
Considering the size of our cohort for both study phases, simultaneously we calculated the statistical power for the different scenarios according to Skol et al. (39) . Supplementary Material, Table S1 , shows the statistical power to detect different effect sizes. On average, we had 86% statistical power to detect an OR of 1.20 with a minor allele frequency of 0.20. Taking this into consideration, for the GWAS analysis three different criteria were followed to select SNPs for replication and maximization of our success in signal detection:
(1) In order to detect common signals for SSc and SLE which caused either risk or protection in both diseases, we selected SNPs that showed a P-value of the SSc and SLE meta-analysis ,5 × 10
27
and showed a nominally significant association with both diseases at a P-value of ,0.05, as well as no significant heterogeneity in the SSc cohorts meta-analysis (Q . 0.05) (Supplementary Material, Table S5 ). (2) To detect common signals for SSc and SLE which caused either risk or protection in one of the diseases and the opposite effect in the other, we selected SNPs that showed a P-value of the SSc and SLE meta-analysis (using for SLE in this case 1/ OR instead of the OR) ,5 × 10 27 and were associated with both a P-value of , 0.05 in both diseases, and without significant heterogeneity in the SSc cohorts meta-analysis (Q . 0.05) (Supplementary Material, Table S6 ). (3) To further detect any susceptibility variants previously reported for one of the diseases but not reported for the other, we selected any SNP with an overall P-value of ,5 × 10 25 and associated separately in SSc and SLE (at a P-value of ,0.05) which had been previously described as a genetic risk factor for either disease (Supplementary Material, Table S7 ).
In any of these cases when performing the pan-meta-analysis of SSc and SLE, we also considered the most frequent SSc subphenotypes (classified as stated above): anti-centromere antibody (ACA) positive subgroup, anti-topoisomerase I antibody (ATA) positive subgroup, limited cutaneous subtype (lcSSc) and diffuse cutaneous subtype (dcSSc) (36, 37) . Supplementary Material, Figure S3 , shows from which subphenotype of SSc each of the selected SNPs was derived from for the replication step.
After the replication stage was completed, we considered a signal to be statistically significant if the combined (SSc and SLE, GWAS and replication cohorts) meta-analysis P-value was ,5 × 10 28 , and if the meta-analysis P-value (GWAS and replication cohorts) for each disease and stage was also significant.
Statistical analysis
Meta-analysis of the SSc GWAS data was performed with the Cochran-Mantel-Haenszel test correcting for the genomic inflation factor lambda (GC correction) (Supplementary Material, Fig. S4 ). Analysis of the SLE GWAS data was performed by a simple x 2 2 × 2 test correcting the P-values for the genomic inflation factor lambda (GC correction) (Supplementary Material, Fig. S4 ). The pan-meta-analysis of the SSc and SLE GWAS data was performed using the inverse variance method calculating the resulting ORs. When the replication cohorts were included in the analysis, they were also analyzed using the inverse variance method. The analysis of the GWAS and replication cohorts together was also performed by means of logistic regression analysis using the first three principal components as covariates in order to rule out any population stratification effect. When different associations were found in the same locus, the underlying association hit was determined by means of conditional logistic regression analysis. All statistical analyses were performed using Plink version 1.07 (40) (http://pngu.mgh.harvard.edu/ purcell/plink/) and HelixTree SNP Variation Suite 7 (http ://www.goldenhelix.com/).
Biological process analysis
We performed the biological process analysis of the SSc and SLE GWAS data according to Zhang et al. (41) . For this, we performed two analyses on each disease, one selecting all SNPs with a P-value ,0.05 and the other selecting all SNPs with a P-value ,5 × 10 26 . In both the cases, the test to determine whether a biological process (GO term) was overrepresented among GWAS associations was performed by means of a hypergeometric test with a cutoff P-value of 5 × 10
26
. All P-values in these analyses were multiple testing corrected according to Hochberg and Benjamini (42) .
Gene expression Data
We had access to whole blood gene expression data from 74 SSc patients, 17 SLE patients and 21 healthy controls (43); which were not included in the GWAS cohorts. None of the patients were treated with immunosuppressive agents (exception prednisone ≤5 mg or hydroxychloroquine). Blood samples for transcript studies were drawn directly into PAXgene tubes (PreAnalytiX, Franklin Lakes, NJ, USA). Total RNA was isolated according to the manufacturer's protocol using the PAXgene RNA kit (PreAnalytiX). The RNA quality and yield were assessed using a 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA) and an ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Two hundred nanograms of total RNA were amplified and purified using the Illumina TotalPrep RNA Amplification kit (Applied Biosystems/ Ambion, Austin, TX, USA) in accordance with the manufacturer's instructions. The amplified complementary RNA was hybridized on Illumina Human Ref-8 BeadChips, and the data were extracted with the Illumina Beadstudio software suite (Illumina, San Diego, CA, USA). A transcript was defined as differentially expressed when the significance level for comparison was P ≤ 0.05 and the FDR was ≤0.10 using a random-variance t-test.
